Organon & Co | OGN - Заемный капитал





Заемный капитал Изменить Дата
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Celltrion KRW 411.27B 998.23M 2026-03
Cspc Pharmaceutical CNY 180.69M 21.94M 2025-12
Deva Holding AS TRY 559.97M 44.39M 2023-09
Dianthus Therapeutics USD 0 0 2024-12
Divis Laboratories Ltd INR 50M 30M 2026-03
Gilead Sciences USD 20.86B 1.27B 2026-03
Glaxosmithkline GBP 18.53B 1.29B 2026-03
Kangmei Pharma CNY 68.57M 9.87M 2026-03
Knight Therapeutics CAD 57.78M 26.92M 2025-12
Laboratorios Farma EUR 80.5M 28.26M 2024-12
Malin Corporation EUR 0 0 2024-12
Medical Developments International AUD 1.5M 167K 2025-12
Merck USD 51.08B 4.41B 2026-06
Novartis USD 37.45B 7.86B 2026-03
Organigram Holdings CAD 60.76M 1.77M 2026-03
Organon & Co USD 8.48B 74M 2026-06
Ovoca Bio EUR 0 0 2021-06
Pharma Mar EUR 32.13M 1.04M 2026-06
Qiagen NV USD 1.63B 19.45M 2026-06
Sartorius EUR 3.65B 311.1M 2026-06
Sino Biopharmaceutical CNY 3.08B 1B 2025-06
Tilray USD 268.59M 3.82M 2025-09
Zealand Pharma A/S 307M 76.14M 2026-03